Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Endometrial Cancer
Interventions: Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Acute Alcoholic Hepatitis
Interventions: Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone; Drug
Lead sponsor: Mack Mitchell; Other
Eligibility: 21 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Surgical Bleeding
Interventions: Raplixa, Gelfoam, Rescue treatment; Drug · Device
Lead sponsor: Mallinckrodt; Industry
Eligibility: Up to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 10 more

Conditions: Anxiety, Caregiver Burden
Interventions: Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Huntington Disease
Interventions: SKY-0515, SKY-0515 Placebo; Drug
Lead sponsor: Skyhawk Therapeutics, Inc.; Industry
Eligibility: 25 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Englewood, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more

Conditions: Enlarged Pores, Sebum Production
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee

Conditions: Marker; Structural
Interventions: Specimen #1, Specimen #2; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 5 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Macular Degeneration
Interventions: pazopanib eye drops, placebo, ranibizumab intravitreal injection; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Mild or Moderate Surgical Bleeding
Interventions: Fibrocaps, Gelatin sponge; Biological
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 721 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: JK07, Matching Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Stanford, California • Boston, Massachusetts • Rochester, Minnesota + 4 more

Conditions: Appetitive Behavior
Interventions: Micellar Casein (#1), Micellar Casein (#2), Calcium Caseinate, Sodium Caseinate, Milk Protein Isolate, Pure Protein Blend, Whey Protein Isolate, Native Whey Protein Isolate, Soy Protein, Pea Protein, Native Whey: Micellar Casein (50:50) blend, Carbohydrate Control; Other
Lead sponsor: Purdue University; Other
Eligibility: 20 Years to 40 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Congenital Hypothyroidism
Interventions: Tirosint®-SOL, Levothyroxine Sodium; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 1 Day to 9 Months
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 7 more

Conditions: DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions: Ketorolac, Dexamethasone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab; Drug · Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more

Conditions: Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
Interventions: Gabapentin, Ketamine, Acetaminophen, Dexamethasone, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Burlington, Vermont • Colchester, Vermont

Conditions: Type 2 Diabetes Mellitus in Obese
Interventions: NDPR diet, USDA healthy eating diet; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammation, Perioperative Morbidity
Interventions: Dexamethasone Sodium Sulfate, Insulin, anesthesia management, Dexamethasone - placebo, Insulin - Placebo, Anesthesia management -Placebo; Drug · Other
Lead sponsor: d sessler; Other
Eligibility: 40 Years to 90 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Nutrition Intervention, Healthy Eating, Diet, Healthy, Hunger, Food Security
Interventions: Nutrition Secure Indianapolis Food Box Intervention, Nutrition Secure Indianapolis Nutrition Education; Other · Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 5 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Chronic Idiopathic Constipation (CIC)
Interventions: Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 109
States / cities: Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Idelalisib, Rituximab, Bendamustine, Placebo to match idelalisib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 23
States / cities: Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Lung Transplant Recipient
Interventions: Anakinra; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Postmenopausal Osteoporosis
Interventions: Romosozumab, Placebo, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 7,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 25
States / cities: Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more

Conditions: Respiratory Disorders
Interventions: NTHi Mcat investigational vaccine (GSK3277511A), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 25
States / cities: Mesa, Arizona • Phoenix, Arizona • Palm Springs, California + 20 more

Search by objective public record fields.

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

Topical Raplixa for Surgical Bleeding in Children

Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults With ADRD

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

A Study of Fibrocaps™ in Surgical Bleeding

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

The Effects of Protein Source on Appetite Control, Satiety, and Subsequent Food Intake

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Pre-Emptive Analgesia in Ano-Rectal Surgery

Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity

The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))

Improving Dietary Quality Through Animal Source Protein Accessibility in a Low-Resource Setting

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.